clofazimine has been researched along with Diarrhea in 6 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy, pharmacokinetics (PK), and safety of clofazimine (CFZ) in patients living with human immunodeficiency virus (HIV) with cryptosporidiosis." | 9.41 | Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial. ( Arnold, SLM; Barrett, LK; Chen, CR; Conrad, TM; Douglas, E; Gordon, MA; Hebert, D; Henrion, M; Hermann, D; Hollingsworth, B; Houpt, E; Iroh Tam, P; Jere, KC; Lindblad, R; Love, MS; Makhaza, L; McNamara, CW; Nedi, W; Nyirenda, J; Operario, DJ; Phulusa, J; Quinnan, GV; Sawyer, LA; Thole, H; Toto, N; Van Voorhis, WC; Winter, A, 2021) |
| "Clofazimine enterophathy is a serious complication of clofazimine when used at high doses for treatment of type 2 lepra or or erythema nodosum leprosum." | 7.75 | [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy]. ( Gómez, Y; López, F; Pinto, R; Rodríguez, G, 2009) |
| " Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose." | 6.87 | Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial. ( Gordon, MA; Hermann, D; Iroh Tam, PY; Nachipo, P; Quinnan, G; Van Voorhis, WC, 2018) |
| "We evaluated the efficacy, pharmacokinetics (PK), and safety of clofazimine (CFZ) in patients living with human immunodeficiency virus (HIV) with cryptosporidiosis." | 5.41 | Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial. ( Arnold, SLM; Barrett, LK; Chen, CR; Conrad, TM; Douglas, E; Gordon, MA; Hebert, D; Henrion, M; Hermann, D; Hollingsworth, B; Houpt, E; Iroh Tam, P; Jere, KC; Lindblad, R; Love, MS; Makhaza, L; McNamara, CW; Nedi, W; Nyirenda, J; Operario, DJ; Phulusa, J; Quinnan, GV; Sawyer, LA; Thole, H; Toto, N; Van Voorhis, WC; Winter, A, 2021) |
| "Clofazimine enterophathy is a serious complication of clofazimine when used at high doses for treatment of type 2 lepra or or erythema nodosum leprosum." | 3.75 | [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy]. ( Gómez, Y; López, F; Pinto, R; Rodríguez, G, 2009) |
| " Primary endpoints include reduction in the number of Cryptosporidium shed in stools over a 5-day period and compared to placebo recipients and the PK of CFZ in plasma assessed by area under the curve, peak plasma concentration, and half-life (T ½) determined after the last dose." | 2.87 | Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial. ( Gordon, MA; Hermann, D; Iroh Tam, PY; Nachipo, P; Quinnan, G; Van Voorhis, WC, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Iroh Tam, P | 1 |
| Arnold, SLM | 1 |
| Barrett, LK | 1 |
| Chen, CR | 1 |
| Conrad, TM | 1 |
| Douglas, E | 1 |
| Gordon, MA | 2 |
| Hebert, D | 1 |
| Henrion, M | 1 |
| Hermann, D | 2 |
| Hollingsworth, B | 1 |
| Houpt, E | 1 |
| Jere, KC | 1 |
| Lindblad, R | 1 |
| Love, MS | 1 |
| Makhaza, L | 1 |
| McNamara, CW | 1 |
| Nedi, W | 1 |
| Nyirenda, J | 1 |
| Operario, DJ | 1 |
| Phulusa, J | 1 |
| Quinnan, GV | 1 |
| Sawyer, LA | 1 |
| Thole, H | 1 |
| Toto, N | 1 |
| Winter, A | 1 |
| Van Voorhis, WC | 2 |
| Huston, CD | 1 |
| Chavez, MA | 1 |
| White, AC | 1 |
| Nachipo, P | 1 |
| Quinnan, G | 1 |
| Iroh Tam, PY | 1 |
| Rodríguez, G | 1 |
| Pinto, R | 1 |
| López, F | 1 |
| Gómez, Y | 1 |
| Desikan, KV | 1 |
| Ramanujam, K | 1 |
| Ramu, G | 1 |
| Balakrishnan, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis[NCT03341767] | Phase 2 | 33 participants (Actual) | Interventional | 2017-12-14 | Terminated (stopped due to Insufficient accrual rate) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for clofazimine and Diarrhea
| Article | Year |
|---|---|
Novel treatment strategies and drugs in development for cryptosporidiosis.
Topics: Animals; Antiprotozoal Agents; Clofazimine; Cryptosporidiosis; Diarrhea; Drug Development; Global He | 2018 |
2 trials available for clofazimine and Diarrhea
| Article | Year |
|---|---|
Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial.
Topics: Adult; Biomedical Research; Clofazimine; Cryptosporidiosis; Cryptosporidium; Diarrhea; HIV; HIV Infe | 2021 |
Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antiprotozoal | 2018 |
3 other studies available for clofazimine and Diarrhea
| Article | Year |
|---|---|
The Clofazimine for Treatment of Cryptosporidiosis in HIV-Infected Adults (CRYPTOFAZ) and Lessons Learned for Anticryptosporidial Drug Development.
Topics: Adult; Clofazimine; Cryptosporidiosis; Diarrhea; Drug Development; HIV Infections; Humans | 2021 |
[Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy].
Topics: Abdominal Pain; Adult; Arthritis, Rheumatoid; Child; Child, Preschool; Clofazimine; Constipation; Di | 2009 |
Autopsy findings in a case of lepromatous leprosy treated with clofazimine.
Topics: Adult; Autopsy; Clofazimine; Diarrhea; Female; Humans; Leprosy | 1975 |